Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. http://www.bmj.com/cgi/content/full/324/7329/71

Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-9. http://content.nejm.org (requires registration)

Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125:328-36.

Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-13.
http://jama.ama-assn.org/cgi/content/full/295/3/306

Buse JB, Ginsberg HN, Bakris GL. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-26. http://circ.ahajournals.org/cgi/content/full/115/1/114

Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med. 1985;313:1369-75.

CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349:1641-9. www.thelancet.com (requires registration)

Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294:914-23. http://jama.ama-assn.org/cgi/content/full/294/8/914

Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003;60:1059-64. http://archneur.ama-assn.org/cgi/content/full/60/8/1059

Dasgupta K, Di Cesar D, Ghosn J, et al. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J. 2006;12:130-5.

De Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89-95. www.thelancet.com (requires registration).

Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183-7. http://www.bmj.com/cgi/content/full/321/7270/1183

Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163:2006-10.

Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzhemier's disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:128. http://www.bmj.com/cgi/content/full/327/7407/128

Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1988;318:262-4.

Fisher M, Knappertz V. The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. Curr Med Res Opin. 2006;22:1239-48.

Frilling B, Schiele R, Kai GittA, et al. Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: results from the MITRA study. Am Heart J. 2004;148:306-11.

Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke. 2005;36:1801-7.

Hansson L, Zanchetti A, Carruthyers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. www.thelancet.com (requires registration)

Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:513S-48S. http://www.chestjournal.org/cgi/content/full/126/3_suppl/172S

He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998;280:1930-5.

Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25:2331-36.

Hennekens CH, Schror K, Weisman S, Fitzgerald GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation. 2004;110:1706-8. http://circ.ahajournals.org/cgi/content/full/110/12/1706

Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-74.

The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349:1569-81. www.thelancet.com (requires registration)

Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340:1421-5.

Krein SL, Vijan S, Pogach LM, et al. Aspirin use and counseling about aspirin among patients with diabetes. Diabetes Care. 2002;25:965-70. Available at http://care.diabetesjournals.org

Laine L, Maller ES, Yu C, et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004;127:395-402.

Mason PJ, Jakobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol. 2005;46:986-93. http://content.onlinejacc.org/cgi/content/full/46/6/986

Masoudi FA, Wolfe P, Havranek EP, et al. Aspirin use in older patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2005;46:955-62. http://content.onlinejacc.org/cgi/content/full/46/6/955

Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of ischemic stroke. Arch Neurol. 2005;62:1217-20. http://archneur.ama-assn.org/cgi/content/full/62/8/1217

Meyer JS, Rogers RL, McClinitic K, et al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc. 1989;37:549-55.

McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624-38.

Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007. http://circ.ahajournals.org/cgi/content/full/115/11/1481

Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111:499-510. http://circ.ahajournals.org/cgi/content/full/111/4/488

Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med. 2001;111:541-5.

Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:S234-S264. Available at http://www.chestjournal.org

Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373-83.

Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Circulation. 2002;106:388. http://circ.ahajournals.org/cgi/content/full/106/3/388

Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296:313-6.

Pignon M, Anderson GK, Binns K, et al. Aspirin use among adults over 40 in the US: Results of a national survey. Am J Prev Med. 2007;32:403-7.

Portnay EL, Foody JM, Rathore SS, et al. Prior aspirin use and outcomes in elderly patients hospitalized with acute myocardial infarction. J Am Coll Cardiol. 2005;46:967-74. http://content.onlinejacc.org/cgi/content/full/46/6/967

Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295-302.

Rahme E, Ghosn J, Dasgupta K, et al. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer. 2005;5:159. http://www.biomedcentral.com/1471-2407/5/159

Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2:349-60.

Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304. http://content.nejm.org/cgi/content/full/352/13/1293

Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet. 1990;336:827-30.

Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes. Estimates from the Third National Health and Nutrition Examination survey. Diabetes Care. 2001;24:197-201. Available at http://care.diabetesjournals.org

Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-90.

Schildkraut JM, Moorman PG, Halabi S, et al. Analgesic drug use and risk of ovarian cancer. Epidemiology. 2006;17:104-7.

Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary or other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol. 2006;47:2130-9. http://content.onlinejacc.org/cgi/content/full/47/10/2130

Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218-24.

Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997;48:626-32.

Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patient undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy Trial Collaborators. Lancet. 1999;353:891-9.

Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet. 1998;351:233-41. www.thelancet.com (requires registration)

U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events. http://www.ahrq.gov/clinic/uspstf/uspsasmi.htm

U.S. Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2007;146:361-64. http://www.ahrq.gov/clinic/uspstf/uspsasco.htm

Viswanathan A, Rakich SM, Engel C, et al. Antiplatelet use after intracerebral hemorrhage. Neurology. 2006;66:206.

Wallentin, LC. Aspirin (75mg/day) after an episode of unstable coronary artery disease; Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol. 1991;18:1587-93.

Wang TH, et al. Aspirin and clopidogrel resistance: an emerging clinical entitity. Eur Heart J. 2006;27:647-54. http://eurheartj.oxfordjournals.org/cgi/content/full/27/6/647